Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines [HPV-16/18 vaccine, GlaxoSmithKline Biologicals (GSK), and HPV-6/11/16/18 vac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Einstein, Mark H, Baron, Mira, Levin, Myron J, Chatterjee, Archana, Fox, Bradley, Scholar, Sofia, Rosen, Jeffrey, Chakhtoura, Nahida, Lebacq, Marie, van der Most, Robbert, Moris, Philippe, Giannini, Sandra L, Schuind, Anne, Datta, Sanjoy K, Descamps, Dominique
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2011
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3338933/
https://ncbi.nlm.nih.gov/pubmed/22048172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.12.18282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados